Atlas Trials

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT06298266 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06298266
Sponsor
Guangdong Second Provincial General Hospital
Status
NOT_YET_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2024-03-29
Primary completion
2026-05-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.